{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:35:26Z","timestamp":1788914126104,"version":"build-2803163510"},"reference-count":38,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"\n Background:<\/jats:bold>\n Chronic spontaneous urticaria (CSU) is a common disease with complex pathogenesis. Patients' clinical characteristics and responses to treatment vary.\n Objective:<\/jats:bold>\n We aimed to investigate the role of data obtained from routinely recommended tests\n in predicting the response to omalizumab, the only biologic agent approved for treatment, and in defining the clinical characteristics of the patients.\n Methods:<\/jats:bold>\n A retrospective study of patients who started omalizumab treatment for CSU between 2015 and 2022 at the Department\n of Dermatology, Pamukkale University, was conducted. Response criteria were based on the urticaria control test, and patients with a urticaria control test score <12 at 6 months were considered treatment non-responders. Eosinophil and basophil counts, neutrophil-lymphocyte ratio (NLR),\n systemic immune inflammation index (SII), systemic inflammation response index (SIRI), and total immunoglobulin E (IgE) levels of the patients were evaluated before treatment and at the sixth month of treatment.\n Results:<\/jats:bold>\n A total of 23.1% of the patients were unresponsive\n to omalizumab. The response rate to the omalizumab treatment of the patients with a total IgE level \u2264 30 IU\/L (n = 4 [5.7%]) was significantly lower than patients with total IgE level > 30 IU\/L (n = 66 [94.3%]) (p\u2009=\u20090.015). The mean \u00b1 standard deviation SIRI levels\n were significantly higher in non-responders versus responders (1.53 \u00b1 1.03 versus 1.15 \u00b1 7.76; p\u2009=\u20090.026). Eosinophil counts positively correlated with basophil counts (r = 587; p\u2009<\u20090.001) and IgE levels (r = 0.290; p\u2009=\u20090.005) but\n a negative correlation was found with levels of NLR (r = \u22120.475; p\u2009<\u20090.001), SIRI (r = \u22120.259; p\u2009=\u20090.013), and SII (r = \u22120.285; p\u2009=\u20090.006). NLR levels were lower in CSU patients with atopy, than in those without atopy (1.9 \u00b1\n 0.9 vs 2.9 \u00b1 2.1,\n p<\/jats:italic>\n = 0.022).\n Conclusion:<\/jats:bold>\n We suggest that eosinopenia and high NLR levels are linked to autoimmune CSU. Predicting a poor response to omalizumab seems possible with total IgE levels < 30 IU\/L and high SIRI levels.\n <\/jats:p>","DOI":"10.2500\/aap.2024.45.240041","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:33:48Z","timestamp":1720571628000},"page":"255-261","source":"Crossref","is-referenced-by-count":5,"title":["What can be learned from real-world data about chronic spontaneous urticaria?"],"prefix":"10.2500","volume":"45","author":[{"given":"Ozge Sevil Karstarli","family":"Bakay","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Pamukkale University Faculty of Medicine, Denizli, Turkey, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Kacar","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Pamukkale University Faculty of Medicine, Denizli, Turkey, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Gul","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Pamukkale University Faculty of Medicine, Denizli, Turkey, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sule","family":"Goksin","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Pamukkale University Faculty of Medicine, Denizli, Turkey, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"Gural","sequence":"additional","affiliation":[{"name":"Division of Statistics, Firat University Faculty of Science, Elazig, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta\u2010analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bjd.19561","article-title":"The global burden of chronic urticaria for the patient and society","volume":"184","author":"Gon\u00e7alo","year":"2021","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/imr.12632","article-title":"The role and relevance of mast cells in urticaria","volume":"282","author":"Church","year":"2018","journal-title":"Immunol Rev"},{"key":"B5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fimmu.2019.00627","article-title":"Autoimmune theories of chronic spontaneous urticaria","volume":"10","author":"Bracken","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fimmu.2019.00627","article-title":"Autoimmune theories of chronic spontaneous urticaria","volume":"10","author":"Nettis","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","article-title":"Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence","volume":"59","author":"Metz","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaip.2019.08.025","article-title":"Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment","volume":"8","author":"Kolkhir","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3906\/sag-1803-87","article-title":"Evaluation of platelet parameters and neutrophil\/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria","volume":"48","author":"Erta\u015f","year":"2018","journal-title":"Turk J Med Sci"},{"key":"B11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15569527.2018.1495227","article-title":"The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria","volume":"38","author":"Acer","year":"2019","journal-title":"Cutan Ocul Toxicol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.anai.2019.08.014","article-title":"New treatments for chronic urticaria","volume":"124","author":"Kolkhir","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2014.04.036","article-title":"The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria","volume":"135","author":"Chang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ijd.14812","article-title":"IFN-\u03b3\/IL-6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy","volume":"59","author":"Grieco","year":"2020","journal-title":"Int J Dermatol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1111\/jdv.16216","article-title":"Omalizumab response correlates with reduced IFN-\u03b3-, IL-10- and IL-31-secreting cells in chronic spontaneous urticaria","volume":"34","author":"Rauber","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/jdv.12831","article-title":"Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels","volume":"30","author":"Altrichter","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bjd.12991","article-title":"Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with low-level persistence in uninvolved skin","volume":"171","author":"Kay","year":"2014","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jaci.2020.03.005","article-title":"The role of eosinophils in chronic spontaneous urticaria","volume":"145","author":"Altrichter","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jdv.14541","article-title":"Different expression patterns of plasma Th1-, Th2-, Th17- and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria","volume":"32","author":"Chen","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41467-022-28172-4","article-title":"Neutrophil extracellular traps and their histones promote Th17 cell differentiation directly via TLR2","volume":"13","author":"Wilson","year":"2022","journal-title":"Nat Commun"},{"key":"B21","first-page":"e14125","article-title":"Clinical and laboratory assessment for the inflammation role in chronic spontaneous urticaria: A clinical study","volume":"33","author":"Ataseven","year":"2020","journal-title":"Dermatol Ther"},{"key":"B22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41435-020-0095-7","article-title":"Evolution and function of interleukin-4 receptor signaling in adaptive immunity and neutrophils","volume":"21","author":"Heeb","year":"2020","journal-title":"Genes Immun"},{"key":"B23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jdermsci.2010.10.013","article-title":"Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis","volume":"61","author":"Hayashida","year":"2011","journal-title":"J Dermatol Sci"},{"key":"B24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.aller.2019.11.007","article-title":"Neutrophil-lymphocyte ratio: a possible marker of remission in children with chronic spontaneous urticaria","volume":"48","author":"Karaman","year":"2020","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B25","first-page":"326","article-title":"Oxidative stress as a key features of autoimmune thyroiditis: An update","volume":"45","author":"Ruggeri","year":"2020","journal-title":"Minerva Endocrinol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1111\/all.14757","article-title":"Predictors of treatment response in chronic spontaneous urticaria","volume":"76","author":"Fok","year":"2021","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1111\/all.13586","article-title":"Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab","volume":"73","author":"Weller","year":"2018","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"B29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","article-title":"Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria","volume":"6","author":"Straesser","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B30","doi-asserted-by":"crossref","first-page":"30","DOI":"10.23822\/EurAnnACI.1764-1489.191","article-title":"Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study","volume":"54","author":"Asero","year":"2022","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1016\/j.jaip.2023.06.026","article-title":"The crucial role of IgE as a predictor of treatment response to omalizumab in chronic spontaneous urticaria","volume":"11","author":"Maurer","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B32","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.jaip.2023.05.033","article-title":"Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis","volume":"11","author":"Chuang","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B33","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1007\/s10067-021-05762-z","article-title":"Systemic inflammatory response index as an independent risk factor for ischemic stroke in patients with rheumatoid arthritis: a retrospective study based on propensity score matching","volume":"40","author":"Jin","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2500\/aap.2023.44.230051","article-title":"Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria","volume":"44","author":"Kulumbegov","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"B35","doi-asserted-by":"crossref","first-page":"e15589","DOI":"10.1111\/dth.15589","article-title":"New markers to predict the response to omalizumab in chronic spontaneous urticaria","volume":"35","author":"Co\u015fansu","year":"2022","journal-title":"Dermatol Ther"},{"key":"B36","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/jcm12072639","article-title":"Chronic urticaria treatment with omalizumab-verification of NLR, PLR, SIRI and SII as biomarkers and predictors of treatment efficacy","volume":"12","author":"Tarkowski","year":"2023","journal-title":"J Clin Med"},{"key":"B37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2024\/00000045\/00000004\/art00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:34:17Z","timestamp":1720571657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2024.45.240041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7,1]]}},"alternative-id":["1088-5412(20240701)45:4L.255;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2024.45.240041","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}